{"id":239,"date":"2026-05-20T10:52:58","date_gmt":"2026-05-20T10:52:58","guid":{"rendered":"https:\/\/epadvisorysolutions.com\/?page_id=5"},"modified":"2026-05-21T07:26:01","modified_gmt":"2026-05-21T07:26:01","slug":"biotech-life-sciences","status":"publish","type":"page","link":"https:\/\/epadvisorysolutions.com\/es\/biotech-life-sciences\/","title":{"rendered":"Biotech &#038; Life Sciences"},"content":{"rendered":"[et_pb_section fb_built=&#8221;1&#8243; fullwidth=&#8221;on&#8221; admin_label=&#8221;Hero Section&#8221; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_fullwidth_header title=&#8221;BIOTECH AND LIFE SCIENCES&#8221; subhead=&#8221;From Pipeline to Commercial&#8221; background_overlay_color=&#8221;rgba(0,0,0,0.8)&#8221; content_max_width=&#8221;700px&#8221; _builder_version=&#8221;4.16&#8243; title_font=&#8221;Poppins|700||on|||||&#8221; title_text_color=&#8221;#edbb5f&#8221; title_font_size=&#8221;14px&#8221; title_letter_spacing=&#8221;2px&#8221; title_line_height=&#8221;1.4em&#8221; content_font=&#8221;Poppins||||||||&#8221; content_font_size=&#8221;16px&#8221; content_letter_spacing=&#8221;1px&#8221; content_line_height=&#8221;2em&#8221; subhead_font=&#8221;Playfair Display|700||on|||||&#8221; subhead_font_size=&#8221;48px&#8221; subhead_letter_spacing=&#8221;3px&#8221; subhead_line_height=&#8221;1.4em&#8221; subhead_text_color=&#8221;#ffffff&#8221; background_color=&#8221;rgba(255, 255, 255, 0)&#8221; background_image=&#8221;https:\/\/epadvisorysolutions.com\/wp-content\/uploads\/2026\/03\/pexels-matthiaszomer-339620-scaled.jpg&#8221; parallax=&#8221;on&#8221; parallax_method=&#8221;off&#8221; header_scroll_down=&#8221;on&#8221; scroll_down_icon_color=&#8221;#edbb5f&#8221; custom_padding=&#8221;8%||260px|&#8221; custom_padding_tablet=&#8221;8%||130px||false|false&#8221; custom_padding_phone=&#8221;||80px||false|false&#8221; custom_padding_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;]\n<p>Capital Allocation &nbsp;\u00b7&nbsp; Commercialisation &nbsp;\u00b7&nbsp; Investor Readiness<\/p>\n[\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Email Strip&#8221; _builder_version=&#8221;4.16&#8243; background_color=&#8221;#1a2540&#8243; custom_padding=&#8221;16px||16px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; max_width=&#8221;1100px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;14px&#8221; text_text_color=&#8221;#ffffff&#8221; text_letter_spacing=&#8221;2px&#8221; text_orientation=&#8221;center&#8221; background_layout=&#8221;dark&#8221; custom_margin=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;]\n<p><span style=\"color: #edbb5f;\">DIRECT CONTACT:<\/span> <a href=\"mailto:eugene@epadvisorysolutions.com\" style=\"color: #ffffff;\">eugene@epadvisorysolutions.com<\/a> &nbsp;\u00b7&nbsp; <a href=\"https:\/\/calendly.com\/eproko2\/discovery-call\" style=\"color: #ffffff;\" target=\"_blank\" rel=\"noopener\">Book a Discovery Call<\/a><\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Floating CTA&#8221; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;0px||0px||true|false&#8221; disabled_on=&#8221;on|on|off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_code _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]\n<div class=\"ep-floating-cta\" style=\"position:fixed;right:30px;top:50%;transform:translateY(-50%);z-index:99;background:#0d1931;border:1px solid #edbb5f;border-top:4px solid #edbb5f;padding:24px 22px;width:215px;box-shadow:0 12px 40px rgba(0,0,0,0.25);font-family:'Poppins',sans-serif;text-align:center;\">\n<div style=\"color:#edbb5f;font-size:11px;letter-spacing:2px;text-transform:uppercase;font-weight:700;margin-bottom:10px;\">Ready to talk?<\/div>\n<div style=\"color:#ffffff;font-family:'Playfair Display',serif;font-size:19px;line-height:1.3;margin-bottom:16px;\">Book a discovery call.<\/div>\n<p><a href=\"https:\/\/calendly.com\/eproko2\/discovery-call\" target=\"_blank\" rel=\"noopener\" style=\"display:inline-block;background:#edbb5f;color:#0d1931;padding:11px 18px;font-size:12px;font-weight:700;letter-spacing:1.5px;text-transform:uppercase;text-decoration:none;border-radius:0;\">Schedule \u2192<\/a><\/p>\n<div style=\"color:rgba(255,255,255,0.55);font-size:10px;letter-spacing:1px;margin-top:14px;line-height:1.5;\">or email<!\u2013- [et_pb_br_holder] -\u2013><a href=\"mailto:eugene@epadvisorysolutions.com\" style=\"color:#edbb5f;text-decoration:none;\">eugene@epadvisorysolutions.com<\/a><\/div>\n<\/div>\n<style>\n@media (max-width: 980px) { .ep-floating-cta { display: none !important; } }\n<\/style>\n[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; background_color=&#8221;#ffffff&#8221; custom_padding=&#8221;100px||100px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; max_width=&#8221;1100px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;16px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; header_2_font=&#8221;Playfair Display|700|||||||&#8221; header_2_text_color=&#8221;#333333&#8243; header_2_font_size=&#8221;38px&#8221; header_2_line_height=&#8221;1.4em&#8221; header_3_font=&#8221;Poppins|700||on|||||&#8221; header_3_text_color=&#8221;#edbb5f&#8221; header_3_font_size=&#8221;14px&#8221; header_3_letter_spacing=&#8221;2px&#8221; header_3_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||30px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]\n<h3>WHAT CLIENTS GET<\/h3>\n<h2>Translating science into investor-ready outcomes.<\/h2>\n[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;17px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; text_orientation=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]\n<p>Most biotechs do not fail to raise capital because they lack good science. They fail because they cannot translate scientific progress into the financial logic investors use to make decisions \u2014 and they start that translation too late. I work from pre-Series A through commercial launch.<\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; background_color=&#8221;#f9f9f7&#8243; custom_padding=&#8221;100px||100px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; max_width=&#8221;1100px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;16px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; header_2_font=&#8221;Playfair Display|700|||||||&#8221; header_2_text_color=&#8221;#333333&#8243; header_2_font_size=&#8221;38px&#8221; header_2_line_height=&#8221;1.4em&#8221; header_3_font=&#8221;Poppins|700||on|||||&#8221; header_3_text_color=&#8221;#edbb5f&#8221; header_3_font_size=&#8221;14px&#8221; header_3_letter_spacing=&#8221;2px&#8221; header_3_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||30px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]\n<h3>PIPELINE CAPITAL ALLOCATION<\/h3>\n<h2>rNPV frameworks and stage-gate discipline.<\/h2>\n[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;17px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; text_orientation=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]\n<p>Risk-adjusted NPV frameworks, stage-gate investment criteria and portfolio prioritisation \u2014 deciding which assets to fund, at what cost, and when to stop. Identifying key risks before capital is committed, not after.<\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; background_color=&#8221;#ffffff&#8221; custom_padding=&#8221;100px||100px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; max_width=&#8221;1100px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;16px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; header_2_font=&#8221;Playfair Display|700|||||||&#8221; header_2_text_color=&#8221;#333333&#8243; header_2_font_size=&#8221;38px&#8221; header_2_line_height=&#8221;1.4em&#8221; header_3_font=&#8221;Poppins|700||on|||||&#8221; header_3_text_color=&#8221;#edbb5f&#8221; header_3_font_size=&#8221;14px&#8221; header_3_letter_spacing=&#8221;2px&#8221; header_3_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||30px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]\n<h3>LAUNCH ECONOMICS<\/h3>\n<h2>Launch P&amp;L built into strategy from day one.<\/h2>\n[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;17px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; text_orientation=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]\n<p>Launch P&amp;L design, peak sales forecasting, payer strategy economics and market access financial modelling \u2014 built into development strategy from the outset. Finance must own that process from the beginning, not validate it at the end.<\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; background_color=&#8221;#ffffff&#8221; custom_padding=&#8221;100px||100px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; max_width=&#8221;1100px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;16px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; header_2_font=&#8221;Playfair Display|700|||||||&#8221; header_2_text_color=&#8221;#333333&#8243; header_2_font_size=&#8221;38px&#8221; header_2_line_height=&#8221;1.4em&#8221; header_3_font=&#8221;Poppins|700||on|||||&#8221; header_3_text_color=&#8221;#edbb5f&#8221; header_3_font_size=&#8221;14px&#8221; header_3_letter_spacing=&#8221;2px&#8221; header_3_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||30px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]\n<h3>BIOTECH LICENSING<\/h3>\n<h2>Deal economics built before the negotiation.<\/h2>\n[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;17px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; text_orientation=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]\n<p>In-licensing and out-licensing decisions hinge on the quality of the underlying financial architecture \u2014 not the deal terms themselves. Risk-adjusted valuation under clinical and commercial uncertainty, deal-structure modelling (upfront\/milestone\/royalty splits), term sheet economics and scenario-tested counterfactuals: what does this asset look like in-house vs partnered, and at what value transfer does each path become rational?<\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; background_color=&#8221;#f9f9f7&#8243; custom_padding=&#8221;100px||100px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; max_width=&#8221;1100px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;16px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; header_2_font=&#8221;Playfair Display|700|||||||&#8221; header_2_text_color=&#8221;#333333&#8243; header_2_font_size=&#8221;38px&#8221; header_2_line_height=&#8221;1.4em&#8221; header_3_font=&#8221;Poppins|700||on|||||&#8221; header_3_text_color=&#8221;#edbb5f&#8221; header_3_font_size=&#8221;14px&#8221; header_3_letter_spacing=&#8221;2px&#8221; header_3_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||30px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]\n<h3>PHARMA PARTNERSHIPS EVALUATION<\/h3>\n<h2>Co-promotion and option deals \u2014 modelled both ways.<\/h2>\n[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;17px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; text_orientation=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]\n<p>Co-promotion, co-development, option agreements and strategic partnerships with large pharma require an internal financial model that frames the deal from the company&#8217;s perspective, not the counter-party&#8217;s pitch deck. Milestone trigger modelling, royalty stack analysis, opt-in\/opt-out economics, and a clear-eyed comparison of partnership economics against the solo-launch case \u2014 built before the term sheet lands.<\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; background_color=&#8221;#f9f9f7&#8243; custom_padding=&#8221;100px||100px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; max_width=&#8221;1100px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;16px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; header_2_font=&#8221;Playfair Display|700|||||||&#8221; header_2_text_color=&#8221;#333333&#8243; header_2_font_size=&#8221;38px&#8221; header_2_line_height=&#8221;1.4em&#8221; header_3_font=&#8221;Poppins|700||on|||||&#8221; header_3_text_color=&#8221;#edbb5f&#8221; header_3_font_size=&#8221;14px&#8221; header_3_letter_spacing=&#8221;2px&#8221; header_3_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||30px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]\n<h3>INVESTOR READINESS<\/h3>\n<h2>Series A\u2013C architecture that survives diligence.<\/h2>\n[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;17px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; text_orientation=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]\n<p>Series A\u2013C fundraising architecture: runway planning, data room design, investor narrative and scenario-tested financial models. The strategic funding architecture that separates companies that raise on their terms from those that don&#8217;t.<\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; background_color=&#8221;#ffffff&#8221; custom_padding=&#8221;100px||100px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; max_width=&#8221;1100px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;16px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; header_2_font=&#8221;Playfair Display|700|||||||&#8221; header_2_text_color=&#8221;#333333&#8243; header_2_font_size=&#8221;38px&#8221; header_2_line_height=&#8221;1.4em&#8221; header_3_font=&#8221;Poppins|700||on|||||&#8221; header_3_text_color=&#8221;#edbb5f&#8221; header_3_font_size=&#8221;14px&#8221; header_3_letter_spacing=&#8221;2px&#8221; header_3_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||30px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]\n<h3>WHAT THAT HAS LOOKED LIKE<\/h3>\n<h2>Track record. Real numbers.<\/h2>\n[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;17px&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; text_orientation=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]\n<p><strong>Benlysta at GSK<\/strong> \u2014 \u00a360m first-year SC launch revenue. 20% YoY franchise growth sustained.<br \/><strong>Clinical Programme Redesign<\/strong> \u2014 \u00a3300m+ portfolio. NPV improved by approximately \u00a3100m through capital allocation discipline.<\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; background_color=&#8221;#0d1931&#8243; custom_padding=&#8221;120px||120px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; _builder_version=&#8221;4.16&#8243; max_width=&#8221;1100px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; text_font=&#8221;Poppins||||||||&#8221; text_font_size=&#8221;17px&#8221; text_text_color=&#8221;#ffffff&#8221; text_letter_spacing=&#8221;1px&#8221; text_line_height=&#8221;2em&#8221; header_2_font=&#8221;Playfair Display|700|||||||&#8221; header_2_text_color=&#8221;#ffffff&#8221; header_2_font_size=&#8221;38px&#8221; header_2_line_height=&#8221;1.4em&#8221; header_3_font=&#8221;Poppins|700||on|||||&#8221; header_3_text_color=&#8221;#edbb5f&#8221; header_3_font_size=&#8221;14px&#8221; header_3_letter_spacing=&#8221;2px&#8221; header_3_line_height=&#8221;2em&#8221; max_width=&#8221;800px&#8221; module_alignment=&#8221;center&#8221; text_orientation=&#8221;center&#8221; background_layout=&#8221;dark&#8221; global_colors_info=&#8221;{}&#8221;]\n<h3>READY TO TALK?<\/h3>\n<h2>Capital Allocation. Commercialisation. Investor Readiness.<\/h2>\n<p>Senior strategic finance for biotech and life sciences companies \u2014 from pre-Series A through commercial launch.<\/p>\n[\/et_pb_text][et_pb_button button_text=&#8221;Book a Discovery Call&#8221; button_url=&#8221;https:\/\/calendly.com\/eproko2\/discovery-call&#8221; url_new_window=&#8221;on&#8221; button_alignment=&#8221;center&#8221; _builder_version=&#8221;4.16&#8243; custom_button=&#8221;on&#8221; button_text_color=&#8221;#0d1931&#8243; button_bg_color=&#8221;#edbb5f&#8221; button_border_width=&#8221;0px&#8221; button_border_radius=&#8221;0px&#8221; button_letter_spacing=&#8221;2px&#8221; button_font=&#8221;Saira Extra Condensed|600||on|||||&#8221; button_icon=&#8221;&#x24;||divi||400&#8243; button_icon_color=&#8221;#0d1931&#8243; custom_padding=&#8221;16px|32px|16px|32px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section]\n","protected":false},"excerpt":{"rendered":"<p>Capital Allocation &nbsp;\u00b7&nbsp; Commercialisation &nbsp;\u00b7&nbsp; Investor ReadinessDIRECT CONTACT: eugene@epadvisorysolutions.com &nbsp;\u00b7&nbsp; Book a Discovery CallWHAT CLIENTS GET Translating science into investor-ready outcomes.Most biotechs do not fail to raise capital because they lack good science. They fail because they cannot translate scientific progress into the financial logic investors use to make decisions \u2014 and they start that [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"nf_dc_page":"","_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-239","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biotech &amp; Life Sciences - EP Advisory<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/epadvisorysolutions.com\/es\/biotech-life-sciences\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biotech &amp; Life Sciences - EP Advisory\" \/>\n<meta property=\"og:description\" content=\"Capital Allocation &nbsp;\u00b7&nbsp; Commercialisation &nbsp;\u00b7&nbsp; Investor ReadinessDIRECT CONTACT: eugene@epadvisorysolutions.com &nbsp;\u00b7&nbsp; Book a Discovery CallWHAT CLIENTS GET Translating science into investor-ready outcomes.Most biotechs do not fail to raise capital because they lack good science. They fail because they cannot translate scientific progress into the financial logic investors use to make decisions \u2014 and they start that [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/epadvisorysolutions.com\/es\/biotech-life-sciences\/\" \/>\n<meta property=\"og:site_name\" content=\"EP Advisory\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-21T07:26:01+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/epadvisorysolutions.com\\\/biotech-life-sciences\\\/\",\"url\":\"https:\\\/\\\/epadvisorysolutions.com\\\/biotech-life-sciences\\\/\",\"name\":\"Biotech & Life Sciences - EP Advisory\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/epadvisorysolutions.com\\\/#website\"},\"datePublished\":\"2026-05-20T10:52:58+00:00\",\"dateModified\":\"2026-05-21T07:26:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/epadvisorysolutions.com\\\/biotech-life-sciences\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/epadvisorysolutions.com\\\/biotech-life-sciences\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/epadvisorysolutions.com\\\/biotech-life-sciences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/epadvisorysolutions.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biotech &#038; Life Sciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/epadvisorysolutions.com\\\/#website\",\"url\":\"https:\\\/\\\/epadvisorysolutions.com\\\/\",\"name\":\"EP Advisory\",\"description\":\"Strategic Finance for Founders, Investors and PE-Backed Businesses\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/epadvisorysolutions.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biotech & Life Sciences - EP Advisory","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/epadvisorysolutions.com\/es\/biotech-life-sciences\/","og_locale":"es_ES","og_type":"article","og_title":"Biotech & Life Sciences - EP Advisory","og_description":"Capital Allocation &nbsp;\u00b7&nbsp; Commercialisation &nbsp;\u00b7&nbsp; Investor ReadinessDIRECT CONTACT: eugene@epadvisorysolutions.com &nbsp;\u00b7&nbsp; Book a Discovery CallWHAT CLIENTS GET Translating science into investor-ready outcomes.Most biotechs do not fail to raise capital because they lack good science. They fail because they cannot translate scientific progress into the financial logic investors use to make decisions \u2014 and they start that [&hellip;]","og_url":"https:\/\/epadvisorysolutions.com\/es\/biotech-life-sciences\/","og_site_name":"EP Advisory","article_modified_time":"2026-05-21T07:26:01+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"11 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/epadvisorysolutions.com\/biotech-life-sciences\/","url":"https:\/\/epadvisorysolutions.com\/biotech-life-sciences\/","name":"Biotech & Life Sciences - EP Advisory","isPartOf":{"@id":"https:\/\/epadvisorysolutions.com\/#website"},"datePublished":"2026-05-20T10:52:58+00:00","dateModified":"2026-05-21T07:26:01+00:00","breadcrumb":{"@id":"https:\/\/epadvisorysolutions.com\/biotech-life-sciences\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/epadvisorysolutions.com\/biotech-life-sciences\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/epadvisorysolutions.com\/biotech-life-sciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/epadvisorysolutions.com\/"},{"@type":"ListItem","position":2,"name":"Biotech &#038; Life Sciences"}]},{"@type":"WebSite","@id":"https:\/\/epadvisorysolutions.com\/#website","url":"https:\/\/epadvisorysolutions.com\/","name":"EP Advisory","description":"Strategic Finance for Founders, Investors and PE-Backed Businesses","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/epadvisorysolutions.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/epadvisorysolutions.com\/es\/wp-json\/wp\/v2\/pages\/239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/epadvisorysolutions.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/epadvisorysolutions.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/epadvisorysolutions.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/epadvisorysolutions.com\/es\/wp-json\/wp\/v2\/comments?post=239"}],"version-history":[{"count":10,"href":"https:\/\/epadvisorysolutions.com\/es\/wp-json\/wp\/v2\/pages\/239\/revisions"}],"predecessor-version":[{"id":373,"href":"https:\/\/epadvisorysolutions.com\/es\/wp-json\/wp\/v2\/pages\/239\/revisions\/373"}],"wp:attachment":[{"href":"https:\/\/epadvisorysolutions.com\/es\/wp-json\/wp\/v2\/media?parent=239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}